Grifols (GIFLF) Other Non-Current Liabilities (2013 - 2025)
Grifols' (GIFLF) quarterly Other Non-Current Liabilities came in at $3.5 million in Q4 2025, up 226.8% on a YoY basis from $1.1 million in Q4 2024, and up 226.8% quarter-over-quarter from $1.1 million in Q4 2024.
Analysis
Grifols (GIFLF) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Other Non-Current Liabilities for 13 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 226.8% year-over-year to $3.5 million; the trailing twelve-month figure through Dec 2025 stood at $3.5 million (up 226.8% YoY), and the FY2025 full-year result was $3.4 million, up 217.19% from the prior year.
- Other Non-Current Liabilities grew to $3.5 million in Q4 2025 per GIFLF's latest filing, from $1.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $380.9 million in Q4 2021 and bottomed at -$3.8 billion in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged -$679.1 million across 5 years, with a median of $3.5 million in 2025.
- The sharpest annual moves came in 2021 and 2023: Other Non-Current Liabilities soared 1849.27% in 2021, then plunged 24905.17% in 2023.
- Over 5 years, Other Non-Current Liabilities stood at $380.9 million in 2021, then sank by 95.98% to $15.3 million in 2022, then sank by 24905.17% to -$3.8 billion in 2023, then jumped by 100.03% to $1.1 million in 2024, then surged by 226.8% to $3.5 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.5 million, $1.1 million, and -$3.8 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 3.49 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | -3.80 Bn |
| Dec 31, 2022 | 15.30 Mn |
| Dec 31, 2021 | 380.94 Mn |
| Dec 31, 2020 | 19.54 Mn |
| Sep 30, 2020 | 661.48 Mn |
| Mar 31, 2020 | 543.55 Mn |
| Dec 31, 2019 | 1.09 Mn |
| Sep 30, 2019 | 497.08 Mn |
| Dec 31, 2018 | 1.48 Mn |
| Sep 30, 2018 | 500.18 Mn |
| Jun 30, 2018 | 2.44 Mn |
| Mar 31, 2018 | 529.17 Mn |
| Dec 31, 2017 | 478.62 Mn |
| Mar 31, 2016 | 3.31 Mn |
| Dec 31, 2015 | 8.08 Mn |
| Dec 31, 2014 | -5.97 Bn |
| Dec 31, 2013 | 618.06 Mn |